The PI3K/AKT Pathway as a Target for Cancer Treatment

被引：635
|
作者：
Mayer, Ingrid A. [1 ,2 ,3 ]
Arteaga, Carlos L. [1 ,2 ,3 ]
机构：
[1] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Breast Canc Program, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA
来源：
ANNUAL REVIEW OF MEDICINE, VOL 67 | 2016年 / 67卷
关键词：
phosphoinositide 3-kinase (PI3K)/AKT; mammalian target of rapamycin (mTOR); pathway inhibitors; breast cancer; lymphoproliferative disorders; mutation; CHRONIC LYMPHOCYTIC-LEUKEMIA; POSITIVE BREAST-CANCER; RENAL-CELL CARCINOMA; PIK3CA MUTATIONS; PHOSPHOINOSITIDE; 3-KINASE; PHOSPHATIDYLINOSITOL; ESTROGEN DEPRIVATION; TYROSINE KINASE; MAMMARY-TUMORS; UP-REGULATION;
D O I：
10.1146/annurev-med-062913-051343
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of this pathway, as a result of these somatic alterations, is associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK are currently in clinical trials, alone or in combination, in both solid tumors and hematologic malignancies. These drugs are the focus of this review.
引用
收藏
页码：11 / 28
页数：18
相关论文
共 50 条
  • [1] PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
    Leiphrakpam, Premila D.
    Are, Chandrakanth
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [2] The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
    Kawauchi, Kiyotaka
    Ogasawara, Toshie
    Yasuyama, Masako
    Otsuka, Kuniaki
    Yamada, Osamu
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (05) : 550 - 559
  • [3] PI3K/Akt/mTOR pathway as a target for cancer therapy
    Morgensztern, D
    McLeod, HL
    ANTI-CANCER DRUGS, 2005, 16 (08) : 797 - 803
  • [4] The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
    Slomovitz, Brian M.
    Coleman, Robert L.
    CLINICAL CANCER RESEARCH, 2012, 18 (21) : 5856 - 5864
  • [5] The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
    Mabuchi, Seiji
    Kuroda, Hiromasa
    Takahashi, Ryoko
    Sasano, Tomoyuki
    GYNECOLOGIC ONCOLOGY, 2015, 137 (01) : 173 - 179
  • [6] Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
    Sarker, Debashis
    Reid, Alison H. M.
    Yap, Timothy A.
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2009, 15 (15) : 4799 - 4805
  • [7] PI3K/Akt signalling pathway and cancer
    Vara, JAF
    Casado, E
    de Castro, J
    Cejas, P
    Belda-Iniesta, C
    González-Barón, M
    CANCER TREATMENT REVIEWS, 2004, 30 (02) : 193 - 204
  • [8] PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
    Li, HaiXia
    Zeng, JianFang
    Shen, Keng
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2014, 290 (06) : 1067 - 1078
  • [9] PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
    HaiXia Li
    JianFang Zeng
    Keng Shen
    Archives of Gynecology and Obstetrics, 2014, 290 : 1067 - 1078
  • [10] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
12345